Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Thangamani, Shankar ^a   Younis, Waleed ^a   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL TOXIN; DAPTOMYCIN; EBSELEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOSELENIUM DERIVATIVE; PSEUDOMONIC ACID; PYRROLE DERIVATIVE;

ANIMAL; BAGG ALBINO MOUSE; BIOFILM; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG REPOSITIONING; FEMALE; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; KERATINOCYTE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PENICILLIN RESISTANCE; PHYSIOLOGY; SKIN; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOLES; BACTERIAL TOXINS; BIOFILMS; CELL SURVIVAL; CELLS, CULTURED; DAPTOMYCIN; DRUG REPOSITIONING; DRUG SYNERGISM; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; KERATINOCYTES; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; ORGANOSELENIUM COMPOUNDS; SKIN; STAPHYLOCOCCAL INFECTIONS;

EID: 84933054771     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11596     Document Type: Article

References (53)

1. Forcade, N.A. et al. Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CAMRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) study. Journal of the American Board of Family Medicine: JABFM 24, 543-550 (2011).
2. Odell, C.A. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections. Current opinion in pediatrics 22, 273-277 (2010).
3. Skiest, D.J. & Cooper, T.W. High recurrence rate of CA-MRSA skin and soft tissue infections. Archives of internal medicine 167, 2527author reply 2527 (2007).
4. Mohammad, H., Thangamani, S. & Seleem, M.N. Antimicrobial peptides and peptidomimetics-potent therapeutic allies for staphylococcal infections. Current pharmaceutical design 21, 2073-2088 (2015).
5. Fischbach, M.A. & Walsh, C.T. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
6. Austin, C.P., Brady, L.S., Insel, T.R. & Collins, F.S. NIH Molecular Libraries Initiative. Science 306, 1138-1139 (2004).
7. Thangamani, S., Mohammad, H., Younis, W. & Seleem, M.N. Drug repurposing for the treatment of staphylococcal infections. Current pharmaceutical design 21, 2089-2100 (2015).
8. Chong, C.R. & Sullivan, D.J. New uses for old drugs. Nature 448, 645-646 (2007).
9. Ashburn, T.T. & Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673-683 (2004).
10. Nozawa, R., Yokota, T. & Fujimoto, T. Susceptibility of methicillin-resistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51). Antimicrobial agents and chemotherapy 33, 1388-1390 (1989).
11. Schewe, T. Molecular actions of ebselen-an antiinflammatory antioxidant. General pharmacology 26, 1153-1169 (1995).
12. Azad, G.K. & Tomar, R.S. Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways. Molecular biology reports 41, 4865-4879 (2014).
13. Muller, A., Cadenas, E., Graf, P. & Sies, H. A novel biologically active seleno-organic compound-I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochemical pharmacology 33, 3235-3239 (1984).
14. Maiorino, M., Roveri, A. & Ursini, F. Antioxidant effect of Ebselen (PZ 51): peroxidase mimetic activity on phospholipid and cholesterol hydroperoxides vs free radical scavenger activity. Archives of biochemistry and biophysics 295, 404-409 (1992).
15. Lu, J. et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 27, 1394-1403 (2013).
16. Chan, G., Hardej, D., Santoro, M., Lau-Cam, C. & Billack, B. Evaluation of the antimicrobial activity of ebselen: role of the yeast plasma membrane H+-ATPase. Journal of biochemical and molecular toxicology 21, 252-264 (2007).
17. Bassani, A.S.P., Banov, D.M. & Lehman, P.A.M. Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model. International journal of pharmaceutical compounding 12, 270-273 (2008).
18. David, M.Z. & Daum, R.S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clinical microbiology reviews 23, 616-687 (2010).
19. Berk, D.R. & Bayliss, S.J. MRSA, staphylococcal scalded skin syndrome, and other cutaneous bacterial emergencies. Pediatric annals 39, 627-633 (2010).
20. Antonelou, M., Knowles, J., Siddiqi, S. & Sharma, P. Recurrent cutaneous abscesses caused by PVL-MRSA. BMJ case reports 2011 (2011).
21. Corey, G.R., Jiang, H. & Moeck, G. Dalbavancin or oritavancin for skin infections. The New England journal of medicine 371, 1162-1163 (2014).
22. Shorr, A.F. et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrobial agents and chemotherapy 59, 864-871 (2015).
23. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature reviews. Drug discovery 6, 29-40 (2007).
24. Lubick, N. Tools for tracking antibiotic resistance. Environmental health perspectives 119, A214-217 (2011).
25. Handa, Y. et al. Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates. Surgical neurology 53, 323-329 (2000).
26. Kobayashi, T., Ohta, Y. & Yoshino, J. Preventive effect of ebselen on acute gastric mucosal lesion development in rats treated with compound 48/80. European journal of pharmacology 414, 271-279 (2001).
27. Parnham, M.J. & Sies, H. The early research and development of ebselen. Biochemical pharmacology 86, 1248-1253 (2013).
28. Singh, N. et al. A safe lithium mimetic for bipolar disorder. Nature communications 4, 1332 (2013).
29. King, M.D. et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Annals of internal medicine 144, 309-317 (2006).
30. Stevens, D.L. et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. The Journal of infectious diseases 195, 202-211 (2007).
31. Diep, B.A. et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. The Journal of infectious diseases 208, 75-82 (2013).
32. Otto, M.P. et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy 68, 1524-1532 (2013).
33. Karau, M.J. et al. Linezolid is superior to vancomycin in experimental pneumonia caused by Superantigen-Producing staphylococcus aureus in HLA class II transgenic mice. Antimicrobial agents and chemotherapy 56, 5401-5405 (2012).
34. Mohamed, M.F., Hamed, M.I., Panitch, A. & Seleem, M.N. Targeting Methicillin-Resistant Staphylococcus aureus with Short Salt-Resistant Synthetic Peptides. Antimicrobial agents and chemotherapy 58, 4113-4122 (2014).
35. Molina-Manso, D. et al. In vitro susceptibility to antibiotics of staphylococci in biofilms isolated from orthopaedic infections. International journal of antimicrobial agents 41, 521-523 (2013).
36. Montgomery, C.P. et al. Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PloS one 8, e69508 (2013).
37. Sharma-Kuinkel, B.K., Zhang, Y., Yan, Q., Ahn, S.H. & Fowler, V.G., Jr. Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. PloS one 8, e60463 (2013).
38. Kuhl, P., Borbe, H.O., Romer, A., Fischer, H. & Parnham, M.J. Selective inhibition of leukotriene B4 formation by Ebselen: a novel approach to antiinflammatory therapy. Agents and actions 17, 366-367 (1986).
39. Fournier, B. & Philpott, D.J. Recognition of Staphylococcus aureus by the innate immune system. Clinical microbiology reviews 18, 521-540 (2005).
40. Jialal, I., Miguelino, E., Griffen, S.C. & Devaraj, S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. The Journal of clinical endocrinology and metabolism 92, 3136-3140 (2007).
41. Wallace, H.J. & Stacey, M.C. Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. The Journal of investigative dermatology 110, 292-296 (1998).
42. Cowin, A.J., Hatzirodos, N., Rigden, J., Fitridge, R. & Belford, D.A. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society 14, 421-426 (2006).
43. Donath, M.Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature reviews. Drug discovery 13, 465-476 (2014).
44. Khanna, S. et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PloS one 5, e9539 (2010).
45. Jacqueline, C. et al. Linezolid Dampens Neutrophil-Mediated Inflammation in Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia and Protects the Lung of Associated Damages. The Journal of infectious diseases (2014).
46. Hu, Y. & Coates, A.R. Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies. The Journal of antimicrobial chemotherapy 68, 374-384 (2013).
47. Huang, L., Dai, T., Xuan, Y., Tegos, G.P. & Hamblin, M.R. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrobial agents and chemotherapy 55, 3432-3438 (2011).
48. McNeil, J.C., Hulten, K.G., Kaplan, S.L. & Mason, E.O. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrobial agents and chemotherapy 55, 2431-2433 (2011).
49. Farrell, D.J., Castanheira, M. & Chopra, I. Characterization of global patterns and the genetics of fusidic acid resistance. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 52 Suppl 7, S487-492 (2011).
50. Morones-Ramirez, J.R., Winkler, J.A., Spina, C.S. & Collins, J.J. Silver enhances antibiotic activity against gram-negative bacteria. Science translational medicine 5, 190ra181 (2013).
51. Stevens, D.L., Maier, K.A. & Mitten, J.E. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrobial agents and chemotherapy 31, 213-218 (1987).
52. Mohamed, M.F. & Seleem, M.N. Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Drug design, development and therapy 8, 1979-1983 (2014).
53. Rioja, I., Bush, K.A., Buckton, J.B., Dickson, M.C. & Life, P.F. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clinical and experimental immunology 137, 65-73 (2004).